• Email Preferences
    • Logout
    loading
  • +44 (0)20 8762 8008
  • Change Language
    [Close]
      • Language English
      • Language Japanese
      LanguageEnglish
  • Home
  • Overview
    • Pandemic
    • Bird Flu
  • Subscribers
    • Overview
    • References
    • Planning Tools
    • Travel Advice
    • Email Sign up
  • Locations
  • Newsroom
    • News
    • Editorials
    • FAQs

Quick Links

  • Home
  • About Us
  • Careers
  • CSR
  • Foundation
International SOS Logo
View Map
  • +44 (0)20 8762 8008 Call for Assistance
    • Language English
    • Language Japanese
    LanguageEnglish
  • Search
    • Email Preferences
    • Logout
    loading
    Member
  • Home
  • Overview
    • Pandemic
    • Bird Flu
  • Subscribers
    • References
    • Planning Tools
    • Travel Advice
    • Email Sign up
  • Locations
  • Newsroom
    • News
    • Editorials
    • FAQs
  • About Us
  • Careers
  • CSR
  • Foundation
  • Pandemic Preparedness
  • 2019-nCoV
Print

COVID-19

 


Public Access

Interactive COVID-19 Data by Location

COVID-19 Case Count Trackers

Education and Communication

COVID-19 FAQs and External Resources

COVID-19 Videos

 

 

 

Member Access

 

Travel Restrictions, Flight Operations and Screening

Digital Passports

COVID-19 Digital Passports


Scientific Update

COVID-19 FAQs

COVID-19 Vaccine

COVID19 Vaccine FAQs

COVID-19 Vaccine FAQs

Variant

COVID-19 Variants

COVID-19 Testing

COVID-19 Treatment

Use of Face Masks by the General Public

COVID-19 Travel Advice


 

COVID-19 Disease and Prevention Article


Sign up for Emails and Alerts

 

Premium Services Member Access

 

 

 

COVID-19 Manager Advice


 

COVID-19 Case Definitions used by different authorities

Impact Tool

Pandemic Local Impact Tool

COVID-19 Communication Material


 

COVID modelling with R0 equations

COVID-19 Modelling

COVID-19 Useful Links


 

HOT TOPICS (PREMIUM ACCESS)

  1. …
  2. 9
  3. 10
  4. 11
  5. 12
  6. 13
  7. …
  • COVID-19 vaccination strategies and deployment in the EU/EEA

    08 September, 2022

    Nearly three-quarters of the EU/EEA population have completed the primary vaccination course...

    COVID-19

  • European statement on COVID-19 booster vaccination with Omicron bivalent adapted vaccines

    06 September, 2022

    EMA and ECDC advice for bivalent COVID-19 booster vaccination...

    COVID-19

  • Inhaled COVID-19 vaccine receives approval

    China // 05 September, 2022

    Inhaled COVID-19 vaccine approved in China...

    COVID-19

  • Omicron-adapted bivalent Moderna vaccine authorised as booster dose

    Canada // 02 September, 2022

    Moderna’s bivalent COVID-19 vaccine to be used as a booster dose...

    COVID-19

  • WHO COVID-19 Weekly Reports August 2022

    31 August, 2022

    WHO summary of COVID-19 global activity suggests...

    COVID-19

  • Infectiousness of SARS-CoV-2 breakthrough infections and reinfections

    31 August, 2022

    A recent study found that prior immunity reduces one's risk of transmission...

    COVID-19

  • AstraZeneca's Evusheld gets EUA

    Japan // Australia // United Kingdom // United States // 30 August, 2022

    Drug approved to prevent COVID-19 in some people...

    COVID-19

  • Report on preparing for future pandemics including priority viruses

    Australia // 29 August, 2022

    Priority virus families include Japanese Encephalitis and Hendra....

    General Articles, COVID-19, Seasonal Flu

  • Swissmedic approves Moderna bivalent COVID-19 booster vaccine

    Switzerland // 29 August, 2022

    The newly authorised booster dose targets Omicron variant BA.1...

    COVID-19

  • Ordering at-home testing kits from U.S. government to be suspended

    United States // 29 August, 2022

    On 2 September, ordering through the U.S. government website will be suspended...

    COVID-19

  • WHO initiates mRNA vaccine technology transfer to African nations

    29 August, 2022

    The World Health Organization (WHO) will tranfer mRNA vaccine technology to at least six African nations...

    COVID-19

  • Novavax approved for use in 12 to 17 year olds

    Australia // 29 August, 2022

    Roll out commences 5 September ...

    COVID-19

  • ECDC COVID-19 overview report for week 33 published

    26 August, 2022

    Week 33 ECDC COVID-19 report published...

    COVID-19

  • Vaccine Update – Vaccinations for 5 to 11 year olds begins

    Bangladesh // 25 August, 2022

    Updates on vaccination in Bangladesh...

    COVID-19

  • COVID-19 incubation shortened over time

    22 August, 2022

    Decreased from 5 days to 3.4 days...

    COVID-19

  • Vaccine Update – Novavax expanded use to include 12-17 year olds

    New Zealand // 21 August, 2022

    The vaccine can be used as a primary series in those aged 12 and older ....

    COVID-19

  • First booster for children aged 5 - 11 years announced

    Canada // 19 August, 2022

    Children aged 5 years and older eligible for first booster...

    COVID-19

  • ECDC weekly COVID-19 Country overview for week 32

    19 August, 2022

    ECDC Weekly COVID-19 update for week 32...

    COVID-19

  • WHO recommends Valneva COVID-19 vaccine, second booster doses

    18 August, 2022

    Valneva's inactivated whole-virus vaccine consists of two doses...

    COVID-19

  • Risk of neurological and psychiatric illnesses after COVID-19 diagnosis

    18 August, 2022

    Risk of neurological and psychiatric illnesses persists within 2 years of infected with COVID-19

    COVID-19

  1. …
  2. 9
  3. 10
  4. 11
  5. 12
  6. 13
  7. …
  • Pandemic Home
  • Privacy
  • Contact Us
  • Feedback
  • Terms and Conditions
Footer Image


GeoNames logo

Additional data provided by

© 2024 International SOS